Similar articles

• Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma.

  Keizman D, Ish-Shalom M, Pili R, Hammers H, Eisenberger MA, Sinibaldi V, Boursi B, Maimon N, Gottfried M, Hayat H, Peer A, Kovel S, Sella A, Berger R, Carducci MA. Keizman D, et al. Eur J Cancer. 2012 May;48(7):1031-7. doi: 10.1016/j.ejca.2012.02.050. Epub 2012 Mar 10. Eur J Cancer. 2012. PMID: 22409947
• Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.

  Beuselinck B, Wolter P, Karadimou A, Elaidi R, Dumez H, Rogiers A, Van Cann T, Willems L, Body JJ, Berkers J, Van Poppel H, Lerut E, Debruyne P, Paridaens R, Schöffski P. Beuselinck B, et al. Br J Cancer. 2012 Nov 6;107(10):1665-71. doi: 10.1038/bjc.2012.385. Br J Cancer. 2012. PMID: 23132391 Free PMC article.
• Kidney cancer: SWITCHing inconsequential.

  Thoma C. Thoma C. Nat Rev Urol. 2015 Jun;12(6):305. doi: 10.1038/nrurol.2015.116. Epub 2015 May 19. Nat Rev Urol. 2015. PMID: 25986758 No abstract available.
• Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone.

  Vrdoljak E, Rini B, Schmidinger M, Omrčen T, Torday L, Szczylik C, Sella A. Vrdoljak E, et al. Anticancer Drugs. 2013 Jun;24(5):431-40. doi: 10.1097/CAD.0b013e328360335f. Anticancer Drugs. 2013. PMID: 23511427 Review.
• Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature.

  Fusco V, Porta C, Saia G, Paglino C, Bettini G, Scoletta M, Bonacina R, Vescovi P, Merigo E, Lo Re G, Guglielmini P, Di Fede O, Campisi G, Bedogni A. Fusco V, et al. Clin Genitourin Cancer. 2015 Aug;13(4):287-294. doi: 10.1016/j.clgc.2014.12.002. Epub 2014 Dec 9. Clin Genitourin Cancer. 2015. PMID: 25586958 Review.